Clinical trials
Lupus or SLE clinical trials
Below are recruiting lupus or sle clinical trials, each written for real people, not researchers. We’re tracking 333 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06691152RecruitingPhase 1
CD19 UCAR T cells for severe lupus
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT07630714RecruitingPhase 2
Testing a new lupus medicine given under the skin in children
This study tests anifrolumab, a new injection medicine that may help control systemic lupus erythematosus (SLE) in children and teens. Researchers will measure how the body processes the medicine and whether it helps reduce lupus activity while monitoring for side effects.
ParkvilleAges 5–17 - NCT07611214RecruitingPhase 4
LUPKYNIS Combined With Immune-Targeting Drugs for Lupus Kidney Disease
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
La Mesa, CaliforniaAges 18–75 - NCT06713187Recruiting
Interleukin-23 study in lupus and lung disease
This trial looks at a protein called interleukin-23 in people with lupus, especially those who also have lung inflammation (interstitial lung disease). The goal is to understand more about this protein's role and possibly find new ways to help.
SohagAges 18–60 - NCT06718283Recruiting
A study of blood tests in young people with lupus
This study looks at blood test results in children and teenagers with lupus to see if they relate to how active the disease is or if it has caused long-term damage. It may help doctors better understand the disease.
SohagAges Up to 18 years - NCT03138941Recruiting
Checking if a lupus control definition fits Asia-Pacific patients
This study tests whether a specific lupus “low disease activity” target (called LLDAS) works the same way in people across the Asia-Pacific region. It may help doctors use clearer goals to track how well lupus is controlled.
Adelaide, South AustraliaAges 18 years+ - NCT02954939Recruiting
Test medicines to change immune cells in lupus kidney flare
This study tests whether mycophenolate mofetil and cyclophosphamide can improve active lupus kidney inflammation by changing immune cell patterns in your blood. It may help patients whose lupus nephritis is currently active, shown by worsening urine protein and/or kidney blood tests.
Hong KongAges 18–80 - NCT06155604RecruitingPhase 2
SGLT2 inhibitor for lupus nephritis with kidney disease
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
Hong KongAges 18 years+ - NCT07509892RecruitingPhase 2
Testing TQH3906 for people with active lupus
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
Bengbu, AnhuiAges 18–74 - NCT07515014RecruitingPhase 2
Testing E6742 in Systemic Lupus Erythematosus
This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.
Bengbu, AnhuiAges 18–75 - NCT06106893RecruitingPhase 1/Phase 2
Study of CD19 CAR-γδT cells for active lupus
This trial is testing a new type of immune cell therapy (called CD19 universal CAR-γδT cells) for people with active lupus that hasn't been well controlled by standard treatments. The goal is to see if these specially designed cells can calm the immune system and reduce lupus symptoms.
Wuhan, HubeiAges 18–70 - NCT06106906RecruitingPhase 1/Phase 2
CD19 CAR-T for Active Lupus
This study tests a new treatment called CD19 CAR-T, which reprograms your own immune cells to attack lupus. It is for people with active lupus that has not responded well to standard therapies.
Wuhan, HubeiAges 18–70 - NCT07440537RecruitingPhase 2
Testing ICP-488 for active cutaneous lupus (skin lupus)
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
Hefei, AnhuiAges 18–75 - NCT07438496RecruitingPhase 3
Study of nipocalimab for moderate to severe lupus
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
Beverly Hills, CaliforniaAges 18–75 - NCT07430306RecruitingPhase 3
Study of anifrolumab for lupus patients not yet on strong treatments
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
Anniston, AlabamaAges 18–70 - NCT07432334RecruitingPhase 1
CAR T-cell therapy for hard-to-treat lupus
This trial tests a personalized treatment called CD19 CAR T-cell therapy for people with severe lupus that hasn't improved with standard treatments. It uses your own immune cells to target and destroy the faulty cells causing lupus symptoms.
HanoiAges 16–55 - NCT07405970RecruitingPhase 3
Testing MIL62 for active lupus
This trial tests an investigational drug called MIL62 for people with systemic lupus erythematosus (SLE) that is still active despite standard treatments. The goal is to see if MIL62 can better control disease activity.
BeijingAges 18–80 - NCT07394361Enrolling by invitation
Clinical Pilates for women with lupus: fatigue and quality of life
This study tests whether clinical Pilates training can help reduce fatigue, improve mood, sleep, and overall quality of life in women with systemic lupus erythematosus. If you have low disease activity and are not already exercising regularly, you may be able to participate.
Adana, SaricamAges 18–55 - NCT07397728Recruiting
TREX1 gene changes in lupus with skin rashes
This trial tests for a specific gene change (in the TREX1 gene) in people with lupus, especially those who have lupus-related skin rashes. It aims to understand how this gene may affect the disease.
Qina, South ValleyAges 18–60 - NCT06841042RecruitingPhase 1/Phase 2
Testing a new drug for active lupus
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
BeijingAges 18–75 - NCT07363590RecruitingPhase 1
Study of MK-1045 for lupus or rheumatoid arthritis
This study tests a new drug, MK-1045, for people with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how it affects your condition.
Southport, QueenslandAges 18–75 - NCT07348055RecruitingPhase 1/Phase 2
A study of GR1803 for lupus
This trial tests a new drug called GR1803 for people with systemic lupus erythematosus (SLE), an autoimmune disease that causes inflammation. It may help reduce disease activity when standard treatments haven't worked well enough.
Wuhan, HubeiAges 18–60 - NCT07330245Recruiting
Study of anifrolumab for lupus patients needing treatment
This study looks at how well anifrolumab works for people with systemic lupus erythematosus (SLE) who are starting it for the first time. It aims to see if patients can achieve a low disease activity state (LLDAS5) after treatment.
Monserrato, CAAges Any age - NCT07323173RecruitingPhase 1
Safety study of LBL-047 in healthy adults and lupus patients
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
Bengbu, AnhuiAges 18–60
Hear when a new Lupus or SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus or sle?
- Yes. Clin2 currently lists 333 recruiting lupus or sle studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus or sle trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus or sle trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.